| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the risk factors for brain apoplexy after VEGF treatment. Our study indicated that hemorrhagic apoplexy developed within 3 months、while thromboembolic apoplexy develop 6 months after VEGF treatment, and related to risk factor of brain infarction including hypertension. Our study revealed that the relationship between tumor location and the lesion of DWI high intensity was important for differentiation between true- and pseudo-response after bevacizumab treatment. Large lipid peaks on 1H-MRS images of tumors without central necrosis were characteristic of malignant lymphomas. Conversely, small or absent lipid peaks in intraaxial tumors without central necrosis were strongly suggestive of glioma. Patients who underwent radiation therapy with primitive neuroectodermal tumors or pineoblastoma developed Zabramski type 1 and 2 CVA significantly earlier than did medulloblastoma patients.
|
